197 related articles for article (PubMed ID: 25963079)
1. Potential Serum Markers for Monitoring the Progression of Hepatitis B Virus-Associated Chronic Hepatic Lesions to Liver Cirrhosis.
Wu C; Liu L; Zhao P; Tang D; Yao D; Zhu L; Wang Z
Gut Liver; 2015 Sep; 9(5):665-71. PubMed ID: 25963079
[TBL] [Abstract][Full Text] [Related]
2. Surface enhanced laser desorption/ionization profiling: New diagnostic method of HBV-related hepatocellular carcinoma.
Wu C; Wang Z; Liu L; Zhao P; Wang W; Yao D; Shi B; Lu J; Liao P; Yang Y; Zhu L
J Gastroenterol Hepatol; 2009 Jan; 24(1):55-62. PubMed ID: 18823443
[TBL] [Abstract][Full Text] [Related]
3. Prediction of chronic hepatitis B, liver cirrhosis and hepatocellular carcinoma by SELDI-based serum decision tree classification.
Cui J; Kang X; Dai Z; Huang C; Zhou H; Guo K; Li Y; Zhang Y; Sun R; Chen J; Li Y; Tang Z; Uemura T; Liu Y
J Cancer Res Clin Oncol; 2007 Nov; 133(11):825-34. PubMed ID: 17516088
[TBL] [Abstract][Full Text] [Related]
4. SELDI-TOF MS proteinchip technology for screening of serum markers of HBV-induced hepatocellular carcinoma.
Geng X; Wang F; Li YG; Zhu GP; Zhang WM
J Exp Clin Cancer Res; 2007 Dec; 26(4):505-8. PubMed ID: 18365545
[TBL] [Abstract][Full Text] [Related]
5. New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples.
Göbel T; Vorderwülbecke S; Hauck K; Fey H; Häussinger D; Erhardt A
World J Gastroenterol; 2006 Dec; 12(47):7604-12. PubMed ID: 17171788
[TBL] [Abstract][Full Text] [Related]
6. Serum peptide profiles during progression of chronic hepatitis B virus infection to liver failure.
Han T; Liu H; Yu ZL; Li J; Wang L; Xiao SX; Li Y; Yu ML
J Viral Hepat; 2010 Mar; 17 Suppl 1():18-23. PubMed ID: 20586930
[TBL] [Abstract][Full Text] [Related]
7. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease.
Zinkin NT; Grall F; Bhaskar K; Otu HH; Spentzos D; Kalmowitz B; Wells M; Guerrero M; Asara JM; Libermann TA; Afdhal NH
Clin Cancer Res; 2008 Jan; 14(2):470-7. PubMed ID: 18223221
[TBL] [Abstract][Full Text] [Related]
8. Plasma lipidomic fingerprinting to distinguish among hepatitis C-related hepatocellular carcinoma, liver cirrhosis, and chronic hepatitis C using MALDI-TOF mass spectrometry: a pilot study.
Passos-Castilho AM; Lo Turco E; Ferraz ML; Matos C; Silva I; Parise E; Pilau E; Gozzo F; Granato C
J Gastrointestin Liver Dis; 2015 Mar; 24(1):43-9. PubMed ID: 25822433
[TBL] [Abstract][Full Text] [Related]
9. Application of serum protein fingerprinting coupled with artificial neural network model in diagnosis of hepatocellular carcinoma.
Wang JX; Zhang B; Yu JK; Liu J; Yang MQ; Zheng S
Chin Med J (Engl); 2005 Aug; 118(15):1278-84. PubMed ID: 16117882
[TBL] [Abstract][Full Text] [Related]
10. Toward the proteomic identification of biomarkers for the prediction of HBV related hepatocellular carcinoma.
He QY; Zhu R; Lei T; Ng MY; Luk JM; Sham P; Lau GK; Chiu JF
J Cell Biochem; 2008 Feb; 103(3):740-52. PubMed ID: 17557278
[TBL] [Abstract][Full Text] [Related]
11. Serum profiling based on fucosylated glycoproteins for differentiating between chronic hepatitis B and hepatocellular carcinoma.
Liao J; Zhang R; Qian H; Cao L; Zhang Y; Xu W; Li J; Wu M; Yin Z
Biochem Biophys Res Commun; 2012 Apr; 420(2):308-14. PubMed ID: 22425980
[TBL] [Abstract][Full Text] [Related]
12. New serum biomarkers for detection of HBV-induced liver cirrhosis using SELDI protein chip technology.
Zhu XD; Zhang WH; Li CL; Xu Y; Liang WJ; Tien P
World J Gastroenterol; 2004 Aug; 10(16):2327-9. PubMed ID: 15285013
[TBL] [Abstract][Full Text] [Related]
13. Natural history of chronic hepatitis B REVEALed.
Chen CJ; Yang HI
J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729
[TBL] [Abstract][Full Text] [Related]
14. Potential proteomic biomarkers in assessing liver fibrosis using SELDI-TOF MS.
Karatayli SC; Alagöz SG; Mizrak D; Sayki M; Ozkan M; Savaş B; Erden E; Cinar K; Idılman R; Yurdaydin C; Bozdayi AM
Turk J Gastroenterol; 2012 Feb; 23(1):46-53. PubMed ID: 22505379
[TBL] [Abstract][Full Text] [Related]
15. SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma.
Schwegler EE; Cazares L; Steel LF; Adam BL; Johnson DA; Semmes OJ; Block TM; Marrero JA; Drake RR
Hepatology; 2005 Mar; 41(3):634-42. PubMed ID: 15726646
[TBL] [Abstract][Full Text] [Related]
16. Identification of beta2-microgloblin as a candidate for early diagnosis of imaging-invisible hepatocellular carcinoma in patient with liver cirrhosis.
Saito Y; Oba N; Nishinakagawa S; Mizuguchi Y; Kojima T; Nomura K; Nakatsura T
Oncol Rep; 2010 May; 23(5):1325-30. PubMed ID: 20372847
[TBL] [Abstract][Full Text] [Related]
17. [The discrepancy of HBsAg titre and HBV DNA in patients with chronic hepatitis B, HBV-related liver cirrhosis and hepatocellular carcinoma].
Pei YZ; Han T; Ma XY; Li Y; Xing J; Song ZL
Zhonghua Gan Zang Bing Za Zhi; 2011 Oct; 19(10):743-6. PubMed ID: 22409845
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of salivary N-glycome in HBV-induced chronic hepatitis, cirrhosis, and hepatocellular carcinoma.
Qin Y; Zhong Y; Ma T; Zhang J; Yang G; Guan F; Li Z; Li B
Glycoconj J; 2017 Aug; 34(4):523-535. PubMed ID: 28389847
[TBL] [Abstract][Full Text] [Related]
19. Complement C4a inhibits the secretion of hepatitis B virus screened by surface-enhanced laser desorption ionization time-flight mass spectrometry-based ProteinChip analysis.
Song YN; Zhang GB; Hu XQ; Lu YY; Zhao Y; Yang Y; Yang YF; Zhang YY; Hu YY; Su SB
Proteomics Clin Appl; 2015 Dec; 9(11-12):1097-104. PubMed ID: 26119402
[TBL] [Abstract][Full Text] [Related]
20. Impacts of human leukocyte antigen DQ genetic polymorphisms and their interactions with hepatitis B virus mutations on the risks of viral persistence, liver cirrhosis, and hepatocellular carcinoma.
Ji X; Zhang Q; Li B; Du Y; Yin J; Liu W; Zhang H; Cao G
Infect Genet Evol; 2014 Dec; 28():201-9. PubMed ID: 25281206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
